Furthermore, the DAF/CD55 was selected to be a potential biomarker for poor prognosis in patients with colon cancer (92, 94), where tumors that express CD55 showed an increase in the CDC resistance (72, 95, 96). This evidence concerns the gene CD55 and malignant colon neoplasm.